Introduction
============

Identification of rare genetic disorders has been greatly improved by the advent of genome-wide sequencing. The new technology has expanded our knowledge of rare disease genetics and enhanced our ability to diagnose new patients.^[@bib1],\ [@bib2]^ However, the diagnosis of rare genetic disorders remains a challenge. Misdiagnoses and delayed diagnoses are often^[@bib3]^ due to nonspecificity and heterogeneity of signs and symptoms, rarity of conditions, and also limited access to the knowledge of highly specialized experts.^[@bib2],\ [@bib4],\ [@bib5]^ Inborn errors of metabolism (IEMs) exemplify these challenges: early signs and symptoms are nonspecific^[@bib6]^ and insufficiently recognized.^[@bib7]^ For example, in a survey of 34 junior pediatric doctors regarding their confidence and knowledge in the acute management of three IEMs---glutaric aciduria type I (MIM 231670), medium-chain acyl Co-A dehydrogenase deficiency (MIM 201450), and maple syrup urine disease (MIM 248600)---only five respondents were able to identify the correct treatment steps for the former two, while only two respondents identified the correct steps for the latter.^[@bib7]^ Moreover, more than 22 respondents indicated a low level of confidence in their knowledge.^[@bib7]^

The knowledge gap between IEM specialists and other clinicians involved in IEM diagnoses is concerning, given the amenability to targeted treatments for an increasing number of IEMs; a delayed diagnosis can lead to irreversible organ damage or even death. Moreover, this disparity is widening with the explosive amount of knowledge generated by multi-omics technology.^[@bib2]^ Such a divide stands in contrast to the historic efforts by the IEM clinical and research community toward early recognition through the creation and use of diagnostic tests, such as population newborn screening. Thus, a potential solution may be found in the rich disease knowledge base established by the IEM community, dating back to Archibald Garrod's study on alkaptonuria in 1902.^[@bib8]^ This compiled knowledge base has, however, lagged behind other fields in the transition to digital form, as much of the work occurred before modern data systems came into existence and therefore the information was stuck on paper. Aspects have been incorporated into large-scale rare-disease databases.^[@bib9],\ [@bib10]^ However, these databases aim to provide an overview of many kinds of individual disorders, and are not designed to guide clinicians in the diagnostic process. Therefore, digital translation and standardization of the IEM community knowledge base are urgently needed to bridge the knowledge gap.

Thus, we created IEMbase, an online application that combines the IEM community knowledge base with a prototype mini-expert system. The expert-compiled knowledge base provides clinical, biochemical, and genetic profiles of 530 known IEMs. The mini-expert system accepts a list of biochemical and clinical phenotypes from users, compares the input phenotypic profile against IEMs in the knowledge base using cosine similarity and semantic similarity, and returns a list of matching IEM diagnoses. With the resulting list, users can generate differential diagnosis charts, biochemical test panels, and targeted gene panels in order to pursue concurrent biochemical and genetic/genomic investigations for a rapid diagnosis. IEMbase aims to renew the existing IEM community knowledge base for the modern age, creating a global resource to facilitate the collection and dissemination of high-quality clinical knowledge for advanced recognition of IEMs.

Materials and methods
=====================

Knowledge base compilation
--------------------------

IEMbase was compiled by extracting 530 disease-characterizing profiles from a nascent disease database, which was previously compiled by more than 100 IEM experts to produce a textbook guide on IEM classification.^[@bib11]^ [Table 1](#tbl1){ref-type="table"} shows an example of an extracted IEM profile. Each IEM profile consisted of known disorder names, disorder abbreviations, causal gene information, a MIM number, and a list of associated biochemical markers and clinical symptoms. Additionally, the list of biomarkers/symptoms was annotated with information regarding onset, severity/pathological level, and whether the biomarker/symptom is characteristic of the associated IEM. The onset information was organized in five categories (neonatal: birth to 1 month, infant: 1--18 months, childhood: 1.5--11 years, adolescence: 11--16 years, and adulthood: \>16 years). The pathological levels of biochemical markers were denoted by up/down/no arrows and the severities of clinical symptoms were denoted by plus/minus signs. The presence or absence of phenotypic characteristics was indicated by yes/no.

The extracted profiles were manually reviewed for consistency and then were imported into IEMbase as three PostgreSQL tables, each representing the type of annotation used in the profiles: disorders, biochemical/clinical phenotypes, or disorder-phenotype associations ([Supplementary Figure S10](#sup1){ref-type="supplementary-material"} online). In total, the tables contained 530 disorders, 2,323 biochemical/clinical phenotypes, and 8,465 disorder-phenotype associations.

Additional annotations were created within each IEM profile. One was the amenability of individual IEMs to treatment, which was manually annotated based on previous literature^[@bib12],\ [@bib13]^ and denoted by yes/no/unknown categories. Another was the prevalence of IEMs as reported in literature or clinical resources.^[@bib9],\ [@bib10],\ [@bib11],\ [@bib13]^ The last was a list of links to relevant entries in external databases, such as UniProt,^[@bib14]^ NCBI Gene,^[@bib15]^ GeneCards,^[@bib16]^ Kyoto Encyclopedia of Genes and Genomes,^[@bib17]^ National Institutes of Health Genetic Testing Registry,^[@bib18]^ and GeneReviews.^[@bib19]^ The links were created for interoperability with existing systems and were created using a BioMart ID conversion tool,^[@bib20]^ as well as URL rules specified on the resource websites.^[@bib18],\ [@bib19]^

The compiled knowledge base was assigned a version number of 1.0.0. This initial version was used for both the methods and the results described herein. Since the initial compilation, IEMbase has been regularly updated with new information. Thus, the version number has been incremented to indicate such updates.

Mapping to structured vocabulary
--------------------------------

A known strategy for matching user-provided phenotypic profiles to diseases is to exploit semantic relationships between phenotypic features, which are defined by a structured vocabulary.^[@bib21]^ The phenotype vocabulary in IEMbase was not structured, but a structure could be imposed based on a compatible external vocabulary. Therefore, the following four standard medical vocabularies were assessed for their compatibility with IEMbase: Human Phenotype Ontology (HPO),^[@bib22]^ Medical Subject Headings (MeSH),^[@bib23]^ Systematized Nomenclature of Medicine--Clinical Terms (SNOMED CT),^[@bib24]^ and International Classification of Diseases, 10th revision (ICD10).^[@bib25]^

During compatibility assessment, HPO OBO file (2016-04-01 release), MeSH ASCII file (2016 version), SNOMED CT RF2 files (2016 versions), and ICD10 XML file (2016 version) were used. The assessment proceeded in three steps. First, unique IDs and medical terms were extracted from IEMbase (version 1.0.0) and the four vocabularies. For SNOMED CT, extraction was restricted to only the terms categorized under "Clinical finding" and "Substance," to minimize false mapping. The OntoCAT R package^[@bib26]^ was used to parse HPO terms. The standard string library and Nokogiri gem in Ruby programming language were used to parse all others. Second, all extracted terms were normalized using the Norm program included in the SPECIALIST Lexical Tools.^[@bib27]^ String normalization removed the differences in alphabetic case, singular or plural variants, punctuations, stop words, and word order. Finally, all IEMbase terms were compared against all terms in each vocabulary. Only the exact matches were recorded as compatible mappings.

The initial compatibility assessment revealed that no single vocabulary could completely cover both the biochemical and the clinical phenotypes in IEMbase ([Table 2](#tbl2){ref-type="table"}). It also revealed that the most compatible vocabulary was different for biochemical (SNOMED CT) and clinical phenotypes (HPO) ([Table 2](#tbl2){ref-type="table"}). Therefore, the assessment was adjusted to consider the two phenotype categories separately. Once adjusted, two additional biochemical vocabularies were added: Chemical Entities of Biological Interest (ChEBI; OBO file; 2016-04-01 release)^[@bib28]^ and Logical Observation Identifiers Names and Codes (LOINC; CSV file; version 2.56).^[@bib29]^

Based on the adjusted assessment ([Table 2](#tbl2){ref-type="table"}), clinical phenotypes were mapped to the most compatible vocabulary, HPO. A medical expert manually reviewed exact matches identified during the compatibility assessment and manually mapped unmatched clinical phenotypes to HPO terms. In total, 1,193 of 1,200 clinical phenotypes were mapped to HPO. The mapped HPO terms and their ancestor/descendant HPO terms were extracted using the OntoCAT R package and were then written into IEMbase as PostgreSQL tables. For biochemical phenotypes, we allowed matches to terms in any of four vocabularies: SNOMED CT, MeSH, LOINC, and ChEBI. However, manual review of unmatched phenotypes revealed that these terms were highly specialized and thus not present in the vocabularies. Therefore, we implemented an alternative strategy for assessing user-supplied biochemical phenotypes and abandoned the established biochemical vocabularies.

Phenotype-matching algorithm for mini-expert system
---------------------------------------------------

The mini-expert system of IEMbase accepts a list of biochemical and clinical phenotypes as input. The system then employs a two-step algorithm that compares the input phenotypic profile against every IEM profile in IEMbase ([Figure 1](#fig1){ref-type="fig"}).

First, the algorithm ranks IEMs by assessing only biochemical phenotypes, using cosine similarity. Cosine similarity^[@bib30]^ is defined as the cosine of two vectors, *TFIDF*~*Q*~ and *TFIDF*~*D*~, which represent the input profile *Q* and an IEM profile *D* from IEMbase. The vectors consist of term frequency--inverse document frequency (*tfidf*) scores^[@bib30]^ defined as follows:

*tf*(*d*, *D*) represents the occurrence of biochemical phenotype *d* in *D*, expressed as 0 or 1. *idf*(*d*, *D*) represents the specificity of *d* to *D*, defined as:

Using the above definitions, the algorithm computes *tfidf* scores for all *d* in *D* and all biochemical phenotypes *q* in *Q*. Individual *tfidf* scores are subsequently multiplied by a score for matching the pathological level (i.e., elevated/normal/decreased), which is −1 if the levels of *d* and *q* do not match or 1 if they match. The algorithm then computes the cosine of vector *TFIDF*~*Q*~ and vector *TFIDF*~*D*~:

The cosine similarity scores are further multiplied by decay factors defined based on severity/characteristics (*sc*) scores for disorder *D*:

*λ* is a decay constant defined between 0.0 and 1.0. *dist* is a Euclidean distance between a vector of *sc* scores for disorder *D* and a vector of maximum possible *sc* scores. The vector of *sc* scores for *D* consists of *sc* scores for individual phenotypes *d* in *D* that match an input phenotype *q* in *Q*. The *sc* score for individual *d* is defined as follows:

*s*(*d*, *D*)is the severity score of *d* ranging from 1 to 3, based on the severity annotation of *d*. *c*(*d*, *D*) is the characteristic score of *d* assigned either 1 or 2, based on whether *d* is characteristic of *D*.

After the initial ranking of IEMs by biochemical phenotypes, the algorithm breaks ties in this ranking by assessing clinical phenotypes using semantic similarity that is computed based on the work of Kohler et al.^[@bib21]^ The similarity between two clinical phenotypes, *p* and *p*′, is computed as the information content (*IC*) of their most informative common ancestor (*MICA*~*p*,*p*′~) in the HPO. *IC* is a measure of concreteness of a phenotype *p* in the HPO. It is defined as:

The similarity between input profile *Q* and an IEM profile *D* is computed by averaging the best match scores for clinical phenotypes *q* in *Q*:

*n*~*q*~ is the number of *q* in *Q*. The best match score for each *q* is defined as *IC(MICA~q~,~d~best~~)*, where *d*~*best*~ is a clinical phenotype in *D* whose common ancestor with *q* has the highest *IC* and the highest severity score. The similarity score is then multiplied by a decay factor as in biochemical similarity.

Software framework details
--------------------------

IEMbase data is stored in a PostgreSQL database. The front-end user interface was developed using an Angular.js framework. The back-end system was developed in a Ruby on Rails framework.

Code availability
-----------------

IEMbase is freely available online (<http://iembase.org/app>) and upon request through an application programming interface. Computer code used for performance evaluation is available upon request.

Mini-expert system case study
-----------------------------

To demonstrate a potential use case scenario of the mini-expert system, we used a case of a delayed diagnosis of hyperornithinemia--hyperammonemia--homocitrullinuria syndrome. Case details are described in the Results section.

Performance evaluation of mini-expert system
--------------------------------------------

To evaluate the performance of IEMbase's mini-expert system, 190 retrospective cases were collected from 15 different metabolic centers. For each case, the contributors provided the final diagnosis and biochemical/clinical information. These cases were collected using an online form, which restricted the contributors to providing the case information using only the disorder and phenotype vocabularies in IEMbase.

Each evaluation case was matched to potential diagnoses using the mini-expert system. The system's performance was compared against three phenotype-matching algorithms, each of which uses cosine similarity, with or without semantic similarity, and also with or without severity and characteristic scores.

In addition, the system performance was compared using only biochemical phenotypes, and only clinical phenotypes of retrospective cases. For each retrospective case, the phenotypes were separated into biochemical and clinical categories before each category was evaluated with the mini-expert system. Eighteen cases with phenotypes only in either category, were excluded from this paired comparison (*n* = 172).

We also tested whether the number of phenotypes specified for each case correlated with the rank of correct diagnoses, in order to assess if some cases ranked better than others because more phenotypes were provided for them.

The above evaluations were conducted using version 1.0.0 of IEMbase. Difference in performance was statistically tested using the Mann-Whitney-U test implemented by wilcox.test in R (version 3.3.1). The correlation test was performed using Spearman's rank correlation test, implemented by cor.test in R. All plots were generated using the ggplot2 R package.

Results
=======

Overview and walkthrough of IEMbase
-----------------------------------

We developed IEMbase as an online application which combines a comprehensive IEM knowledge base with a diagnosis support (mini-expert) system. IEMbase curates expert-provided information on 530 IEMs, their treatability and genetics, as well as associated biochemical/clinical phenotypes with detailed annotations on the onset/severity/pathological level of the phenotypes. The application is freely available and can be accessed at <http://www.iembase.org/app>, or from a link on the project overview website (<http://www.iembase.org>). IEMbase is also available through an application-programming interface for integration into other computational systems. Application-programming interface access is available upon request.

A detailed walkthrough of the application is presented in the [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"}.

Applying mini-expert system in clinical settings
------------------------------------------------

We demonstrate the utility of IEMbase's mini-expert system using a case of a delayed hyperornithinemia--hyperammonemia--homocitrullinuria (HHH) syndrome diagnosis. A girl 2 years and 8 months of age had shown inconspicuous psychomotor development. Following an upper respiratory tract infection, she developed recurrent vomiting, while refusing feeding but drinking occasionally. She was slightly lethargic. Over the following weeks she never fully recovered and continued to undergo episodes of postprandial vomiting, lethargy, and apparent seizures reminiscent of absences. Laboratory tests revealed hyperammonemia (260 μmol/L) together with the constellation of acute liver failure (ASAT 130 U/l, ALAT 233 U/l, ALP 267 U/l, Quick 10%, INR 4.87, aPTT 52 sec.). Plasma amino acids demonstrated high to normal glutamine, elevated ornithine, and low citrulline and arginine, all as abnormalities. Orotic acid was highly elevated in urine. Homocitrulline was specifically tested for but could not be identified in plasma or urine. With a presumptive diagnosis of ornithine transcarbamylase deficiency, the patient was referred to a metabolic center and treated, accordingly, with protein restriction and ammonia scavengers. Over the following months, there were several similar episodes, usually triggered by minor intercurrent infections. Molecular analysis of ornithine transcarbamylase was negative.

When the constellation of symptoms was entered into the IEMbase's mini-expert system ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}), hyperornithinemia--hyperammonemia--homocitrullinuria syndrome was suggested as the most likely disease candidate, while ornithine transcarbamylase deficiency was listed as the second probable disease candidate. Indeed, molecular analysis of *SLC25A15* identified biallelic variants in the gene, confirming the diagnosis of hyperornithinemia--hyperammonemia--homocitrullinuria syndrome and enabling targeted treatment.

Mini-expert system performance evaluation
-----------------------------------------

IEMbase's mini-expert system matched 62% of cases to exact diagnoses, 86% of cases within the top five candidate disorders, and 90% of cases within the top ten. The performance comparison between the mini-expert system algorithm (combined + weighted) and three other phenotype-matching algorithms (combined + unweighted, cosine + weighted, cosine + unweighted) is shown in [Table 3](#tbl3){ref-type="table"} and [Supplementary Figure S11](#sup1){ref-type="supplementary-material"}. There was no significant difference in performance between the mini-expert algorithm and the alternative phenotype-matching algorithms. Cases that were ranked out of the top 20 tended to have entries of unspecific biochemical markers, such as "Acylcarnitines, all" or "Amino acids, all." Refer to [Supplementary Table S2](#sup1){ref-type="supplementary-material"} for an overview of the cases and their ranks. Refer to [Supplementary Table S3](#sup1){ref-type="supplementary-material"} for more information about the cases that were ranked out of the top 20.

The system performance using only biochemical queries was significantly better than using only clinical queries (*P* \< 2.2e^-16^; [Figure 2](#fig2){ref-type="fig"} and [Supplementary Table S4](#sup1){ref-type="supplementary-material"}). Using only biochemical phenotypes, 60% of cases were matched to exact diagnoses, 83% of cases within the top five candidate disorders, and 89% of cases within the top ten. The success rate of biochemical phenotypes plateaued after 90%, as the number of assessed candidates increased, reflecting 13 cases which failed to produce candidates owing to insufficient/unspecific biochemical information and/or the system's inability to recognize similar biochemical phenotypes. As an example of the latter, the current implementation fails to recognize "Acylcarnitines, all" and "Long-chain acylcarnitine" as related phenotypes. Using only clinical phenotypes, only 19% of cases were matched to exact diagnoses, 38% of cases within the top five candidate disorders, and 49% of cases within the top ten.

There was no significant correlation between the rank of correct diagnoses and the number of provided phenotypes (*P* = 0.69; [Supplementary Figure S12](#sup1){ref-type="supplementary-material"}).

Discussion
==========

Although disease databases for IEMs have been developed in the past,^[@bib31],\ [@bib32],\ [@bib33]^ they were either based on individual case reports^[@bib31],\ [@bib32]^ or more focused on specific symptoms, such as intellectual disability.^[@bib33]^ Large-scale rare disease databases currently available for a general clinical audience^[@bib9],\ [@bib10]^ do cover a wide range of rare diseases, but by their nature do not provide the depth of information found in specialized expert knowledge bases. IEMbase is designed to fill this gap, by combining a central knowledge repository with a basic diagnostic support system. This design allows simultaneous collection of the current expert knowledge and its dissemination to the broader clinical community. In addition, it leads to further improvement of the mini-expert system as the depth of knowledge is compiled. Curated knowledge bases are intended to surpass the capacity of any single expert. IEMbase is therefore of utility for all those involved in IEM diagnoses: pediatricians, internists, neurologists, geneticists, and metabolic specialists. As our case study demonstrates, the utility of IEMbase can also be extended to established metabolic centers and biochemical genetics laboratories to help broaden the array of potential differential diagnoses---specifically to include lesser-known diseases when their constellations overlap with typical presentations of better-known diseases.

The evaluation of the mini-expert system revealed that phenotype-matching performance is significantly higher with the use of biochemical phenotypes than that of clinical phenotypes. This probably reflects two influences: (i) many clinical features of IEMs are not specific, while biochemical alterations are frequently so^[@bib6],\ [@bib34]^ and (ii) the IEM community has made intense efforts toward both disease-specific biomarker discovery and the annotation of biochemical phenotypes.^[@bib11],\ [@bib12],\ [@bib34],\ [@bib35]^ The second point draws upon a hundred years of IEM community efforts, leading to a depth and breadth of biochemical annotations that constitute a phenome space well suited to research of assisted diagnostic methods. Furthermore, the uniting of biochemical annotations with genetic and clinical annotations aligns with the imminent shift in investigative paradigm, where multi-omics technology allows holistic investigation into an individual's genome, epigenome, transcriptome, proteome, metabolome, and phenome.^[@bib34]^ Extrapolating from our experience, the knowledge bases of other clinical communities may hold untapped high-quality offline information which could be renewed in a similar way to that held in IEMbase.

Owing to a lack of compatible structured vocabulary for biochemical phenotypes in IEMbase, the current mini-expert system algorithm uses a nonsemantic information retrieval metric (tfidf-cosine similarity) to compare biochemical phenotypes. We recognize that this approach is not robust when matching imprecise terms. For example, the use of tfidf-cosine similarity will not take into account the fact that neopterin and biopterin belong to the same group of pterins. The use of structured vocabulary and semantic similarity can mitigate this shortcoming. Therefore, we plan to contribute our biochemical vocabulary to existing ontologies as we make updates to our system.

Biochemical test/gene panel suggestions that are provided with the output of the mini-expert system are currently restricted to basic information (e.g., gene names or chemical test panels), as detailed specification will require future contributions from the expert community. We anticipate that such improvements will be introduced over time as a result of community outreach efforts such as those described below.

For the long-term viability of IEMbase, continuous contribution from the expert community is crucial, especially with the large number of novel IEMs and phenotypes now being revealed with the use of multi-omics technologies. Therefore, we will periodically reach out to the IEM community for knowledge contribution, in addition to assembling an expert panel, which will regularly review and update the knowledge base. To encourage adoption among the new generation of clinicians, we plan to develop a mobile version of the application and a training module.

In summary, IEMbase is a web application intended to provide the clinical community with a comprehensive IEM knowledge base and a tool to facilitate early and accurate diagnoses of IEMs. Its knowledge base features expert-curated clinical resources on 530 IEMs. Its mini-expert system empowers clinicians and complements their workflow with suggested diagnoses, differential diagnosis charts, biochemical test panels, and gene panels. The multitude of suggestions enables clinicians to initiate concurrent biochemical and genetic evaluations, where the former can help focus the latter for rapid diagnosis, especially in clinical exome/genome interpretations. We believe that the power of IEMbase comes from the community of experts who contribute their knowledge for the greater benefit of the broader clinical community and as such, the value of community science should be recognized as a key component of digital medicine in the 21st century.
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![**Mini-expert algorithm flowchart**. Users enter a list of biochemical/clinical phenotypes into IEMbase's mini-expert system. The system's phenotype-matching algorithm first divides the input list into biochemical and clinical categories. The algorithm then ranks the disorders in IEMbase by comparing the biochemical profile of each disorder against the input biochemical profile, using cosine similarity. Subsequently, the algorithm breaks ties in the ranked list by comparing the clinical profiles, using semantic similarity.](gim2017108f1){#fig1}

![**Mini-expert system performance using only biochemical/clinical information.** The system performance when using only biochemical phenotypes was compared with that when using only clinical phenotypes of 172 retrospective cases. Percentage success N measures % of cases whose actual diagnoses ranked within the top N ranks. The system performance when using only biochemical phenotypes was significantly better than that when using only clinical phenotypes (*P* \< 2.2e-16; Mann-Whitney-U).](gim2017108f2){#fig2}

###### An example disorder profile extracted from the nascent database

                                                                                                                                                                                                                                                
  ------------------------------------------------------------------------------- ---------------------------------- ---------------------------- ------------------------------- -------------------------------- ---------------------------- -----------------------------------
  Disorder name                                                                   Sepiapterin reductase deficiency                                                                                                                              
  Disorder abbreviation                                                           SRD                                                                                                                                                           
  Associated gene                                                                 *SPR*                                                                                                                                                         
  Chromosomal localization                                                        2p14--p12                                                                                                                                                     
  Affected protein                                                                Sepiapterin reductase                                                                                                                                         
  MIM number                                                                      182125                                                                                                                                                        
  **Affected biochemical markers/clinical symptoms**[a](#t1-fn2){ref-type="fn"}   **Neonatal (birth--1 month)**      **Infancy (1--18 months)**   **Childhood (1.5--11 years)**   **Adolescence (11--16 years)**   **Adulthood (\>16 years)**   **Is characteristic of disease?**
  Axial hypotonia                                                                 ++                                 ++                           ++                              \+                               ?                            No
  Cerebral palsy                                                                  ?                                  ?                            ±                               ±                                ±                            Yes
  Eye movements, abnormal                                                         ±                                  ±                            ±                               ?                                ?                            No
  Hypokinesia                                                                     \+                                 ++                           ±                               ±                                ±                            Yes
  Muscle weakness                                                                 \+                                 ±                            ±                               ±                                ?                            No
  5-Hyroxyindoleacetic acid, 5HIAA (cerebrospinal fluid)                          ↓↓↓                                ↓↓↓                          ↓↓↓                             ↓↓↓                              ↓↓↓                          Yes
  Biopterin (cerebrospinal fluid)                                                 ↑                                  ↑                            ↑                               ↑                                ↑                            Yes
  Biopterin (urine)                                                               n                                  n                            n                               n                                n                            No
  Dihydrobiopterin (cerebrospinal fluid)                                          ↑↑                                 ↑↑                           ↑↑                              ↑↑                               ↑↑                           Yes
  Homovanillic acid, HVA (cerebrospinal fluid)                                    ↓↓↓                                ↓↓↓                          ↓↓↓                             ↓↓↓                              ↓↓↓                          Yes
  Neopterin (cerebrospinal fluid)                                                 n                                  n                            n                               n                                n                            No
  Neopterin (urine)                                                               n                                  n                            n                               n                                n                            No
  Phenylalanine (plasma)                                                          n                                  n                            n                               n                                n                            Yes
  Prolactin (plasma)                                                              ↑                                  ↑                            ↑                               ↑                                ↑                            Yes
  Sepiapterin (cerebrospinal fluid)                                               ↑↑                                 ↑↑                           ↑↑                              ↑↑                               ↑↑                           Yes
  Sepiapterin (urine)                                                             ?                                  ↑↑                           ↑↑                              ↑↑                               ?                            Yes

For clinical symptoms, + denotes their presence and ± denotes occasional absence/presence. For biochemical markers, ↑ denotes elevated values, ↓ decreased values, and n denotes normal values. ? denotes uncertain/unreported presence of biomarkers/symptoms.

The affected biochemical markers and clinical symptoms are selected for brevity.

###### Vocabulary compatibility assessment results

              **Biochemical (no. phenotypes mapped)**   **Clinical (no. phenotypes mapped)**   **Total (no. phenotypes mapped)**
  ----------- ----------------------------------------- -------------------------------------- -----------------------------------
  HPO         0                                         450                                    450
  ICD 10      6                                         92                                     98
  SNOMED CT   371                                       389                                    760
  MeSH        324                                       283                                    607
  ChEBI       301                                       3                                      304
  LOINC       367                                       61                                     428

ChEBI, Chemical Entities of Biological Interest; HPO, Human Phenotype Ontology; ICD 10, International Classification of Diseases, 10th revision; LOINC, Logical Observation Identifiers Names and Codes; MeSH, Medical Subject Headings; SNOMED CT, Systematized Nomenclature of Medicine--Clinical Terms.

Total number of biochemical phenotypes in IEMbase is 1,123. Total number of clinical phenotypes in IEMbase is 1,200. Total number of phenotypes in IEMbase is 2,323.

###### Mini-expert system performance evaluation results

                     **Combined + weighted (mini-expert system)**   **Combined + unweighted**   **Cosine + weighted**   **Cosine + unweighted**
  ------------------ ---------------------------------------------- --------------------------- ----------------------- -------------------------
  MRR                0.72                                           0.70                        0.72                    0.68
  \% success at 1    62                                             59                          63                      57
  \% success at 5    86                                             85                          85                      83
  \% success at 10   90                                             91                          90                      89
  \% success at 20   93                                             92                          92                      91

Mean reciprocal rank (MRR) measures how close the correct match is to the top rank on average. It ranges from 0 to 1, and values close to 1 indicate that correct matches appear closer to the top on average. % success at *N* = % of cases with correct diagnoses within top *N* ranks. Combined = combined cosine and semantic similarity. Cosine = cosine similarity only.
